Article Title: Indian consensus on the management of carbapenem-resistant enterobacterales infection in critically ill patients II (ICONIC II)
Authors: Soman, R., Veeraraghavan, B., Hegde, A., et al
Journal: Expert Review of Anti-infective Therapy
Bibliometrics: Volume 22, Number 06, pages 453-468
DOI: http://dx.doi.org/ 10.1080/14787210.2024.2360116
The article was published online with incorrect information in the declaration of interest and funding sections. These have now been corrected in the final version online as follows:
Declaration of Interest
RS has received payment or honoraria for lectures, presentations and participated in advisory board of Pfizer, MSD, Mylan, Cipla, Glenmark and Hoffmann la Roche. AH has served on the advisory of Pfizer, Glenmark, Fusion, Cipla. ST has served on the advisory of Cipla, Pfizer, MSD. RKS has served on the advisory of Cipla, Pfizer, MSD, Glenmark, Fusion, Sanofi, Astra Zeneca. VN has served on the advisory of Cipla, Pfizer, Astellas, Glenmark, Fusion, Mylan. CR is on a scientific advisory board of Pfizer, Sanofi, Biomerieux and has speaker agreements with Sanofi, Becton Dickinson, Cipla, Glenmark, Novartis and Cepheid. SS has served on the advisory of Mylan, Pfizer, Sanofi. AP, SB, SP, HB are employees of Glenmark Pharmaceuticals Ltd and declare no conflict of interest. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. The rest of the authors declare no conflict of interest.
Funding:
This work was supported by Glenmark Pharmaceuticals Ltd.